The ongoing World Health Organization (WHO) Solidarity Trial of hydroxychloroquine, remdesivir, lopinavir, or interferon-beta-1a for the treatment of COVID-19 were found not to prevent in-hospital death, reduce need for ventilation, or shorten duration of hospitalization. The results have been published in the New England Journal of Medicine. The open-label study …
Read More »
Even though the World Health Organization has published the largest randomized trial showing that remdesivir showed no benefit on reducing hospital stays or mortality, the drug has been approved by the U.S. FDA for standard of care use for hospitalized COVID-19 patients. The approval was based on a study by …
Read More »
Results of a World Health Organization coordinated study show that remdesivir has “little or no effect on mortality” for patients hospitalized with coronavirus, and that it doesn’t seem to help patients recover any faster. Till date, this antiviral drug was the only drug that the US FDA had granted COVID-19 …
Read More »
Medicosnext